

Form PTO-1449			ATTY. DOCKET NO. 0204	APPLICATION NO. to be assigned 08/93243 \footnote{1}				
PATENT & TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT			APPLICANT DAVID PORUBEK, ANIL M. KUMAR AND CHARLES R. BREDL					
(II) and the state of the state			FILING DATE GROUP ART UNIT:					
	(Use several sheets if necessary)		October 25, 1994 ENT DOCUMENTS		to be assig	ned		
EXAMINER		0.0.1111	DIVIDOCOMENTO	T	SUB	FILIN	G DATE	
INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	CLASS		ROPRIATE	
	COT							
	06	· , · · · - · · · ·				ļ		
·	REGA.	-				 	v	
					 			
· · · · · · · · · · · · · · · · · · ·							<u></u>	
		<u></u>						
					,			
				_	 			
	F	OREIGN P	ATENT DOCUMENTS					
	SUB TRANSI						LATION	
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	CLASS			
		_				YES	NO	
		· · · · · · · · · · · · · · · · · · ·						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)								
11B F		Allevi et al., Tetrahedron Letters, Vol. 33, No. 33, pp. 4831-4834, "A Short and Simple Synthesis						
// /		the Antitumor Agent Etoposide", 1992.						
MB 1	Bundgaard, et al., J. Med. Chem., Vol. 32, No. 12, pp. 2503-2507, "A Novel Solution-Stable, Water-Soluble Prodrug Type for Drugs Containing a Hydroxyl or an NH-Acidic Group", 1989.							
/// / 	Hussain et al., J. Pharma. Sci., Vol. 76, No. 5, pp. 356-358, "Improvement of the Oral Bioavailability of							
M3 I	Naltrexone in Dogs: A Prodrug Approach", 1987.							
1,00	Riley et al., J. Chem. Education, Vol. 65, No. 11, pp. 947-953, "The Prodrug Concept and New Drug Design							
-W'/	and Development", 1988.							
· · /								
<u> </u> -								
-			······································					
EXAMINER MILL 1) Ball			1	DATE CONSIDERED				
	// Con	veu		<u> </u>	- 1/83			
	tial if citation considered, whether				aw line throu	igh citatio	n if not	